RxDoctor Payments Data

Emma Diiorio, MD

Rheumatology · Rockville, MDNPI 1528067808

Payments from drug & device makers

$980in general payments, 2019–2025

Across 42 payments — averaging $23.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$288
  • Johnson & Johnson$216
  • AstraZeneca$178
  • Aurinia Pharma U.S., Inc.$113
  • Boehringer Ingelheim$42
  • Pfizer$34
  • plus $108 from 7 others

What the payments were for

  • Food & beverage$86088%
  • Education$11912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$980 in reported general payments places this provider in the 30th percentile of 173 rheumatology providers in Maryland.

See all rheumatology providers in Maryland

Medicare billing

Part B allowed, 2024
$3,679,760
Medicare patients
1,293
Services billed
195,002

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EnbrelEtanercept29$359,303
HumiraAdalimumab26$288,377
Humira(Cf) PenAdalimumab19$284,898
TymlosAbaloparatide58$251,454
Enbrel SureclickEtanercept16$164,572
Cosentyx Sensoready (2 Pens)Secukinumab11$79,774
Xeljanz XrTofacitinib Citrate12$68,293
SavellaMilnacipran Hcl11$14,000
Hydroxychloroquine Sulfate132$7,530
MethotrexateMethotrexate Sodium167$6,297
Alendronate Sodium234$2,364
Mycophenolate Mofetil19$2,332
Duloxetine Hcl63$2,137
Celecoxib48$1,495
Prednisone125$1,354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$288$359,30329 claims
AbbVieHumira, Savella$14$302,37737 claims
Radius Health, Inc.Tymlos$14$251,45458 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 173 rheumatology providers in Maryland.

Other rheumatology in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →